ライフサイエンスコーパス: HIV-negative

1 e likely than other tuberculosis cases to be HIV negative.

2 , even if they perceive their partners to be HIV negative.

3 (aged 3 years or older and immunocompetent [HIV-negative]).

4 Of 745 patients (374 HIV-infected, 371 HIV-negative), 15.7% were colonized with CA-MRSA at any

5 ly tested for syphilis annually increased in HIV-negative (48% to 91%; Ptrend < .0001) and HIV-positi

6 ne responses to PARV4 in a group of HCV- and HIV-negative, active intravenous drug users.

7 treatment success only in patients who were HIV negative (adjusted OR 4.12 [95% CI 2.25-7.54]) or wh

8 and survival in 516 HIV-positive and 93,027 HIV-negative adult kidney-only recipients using Scientif

9 , double-blinded dose-escalation study in an HIV-negative adult South African cohort (n = 72) with ac

10 ed with EDTA plasma (n = 1,301) and DBS from HIV-negative adults (n = 1,000).

11 nd children, respectively, compared to 9% in HIV-negative adults and children.

12 oup, multicentre phase 2 trial, we recruited HIV-negative adults with de novo or transformed DLBCL an

13 une responses can be found in not only older HIV-negative adults, but also adults with HIV infection.

14 contributing to prevention services for the HIV-negative adults.

15 e same year and in only individuals who were HIV-negative, all-form tuberculosis incidence was 7.1 mi

16 2304 PWIDs were recruited, 1200 of whom were HIV negative and are included in the present study.

17 transgender women aged 18-70 years who were HIV negative and had participated in three previous PrEP

18 ding in Brazil, Mexico, and the USA who were HIV negative and reported no history of anogenital cance

19 (ARV) drugs by human immunodeficiency virus (HIV)-negative and -positive individuals to reduce HIV ac

20 f T cells from human immunodeficiency virus (HIV)-negative and HIV-infected men to peptide pools span

21 %-12.3%) among human immunodeficiency virus (HIV)-negative and HIV-positive persons, respectively.

22 Blood and semen were collected from 42 HIV-negative and 38 HIV-positive men.

23 There is also a group of HIV-negative and HHV-8-negative patients with unknown et

24 In conclusion, HIV-negative and HIV monoinfected kidney transplant reci

25 analyse differences in HRQoL scores between HIV-negative and HIV-positive individuals who were unawa

26 799 and 1032 syphilis cases were detected in HIV-negative and HIV-positive MSM, respectively.

27 ncommon cause of ocular inflammation in both HIV-negative and HIV-positive patients.

28 In this prospective study, we enrolled HIV-negative and HSV2-negative women aged 15-49 years wh

29 We enrolled HIV-negative and human herpesvirus-8-seronegative patien

30 0.06/EY (95% CI: 0.002/EY-0.35/EY) among the HIV-negative and the HIV-positive patients, respectively

31 0.12/EY (95% CI: 0.01/EY-0.42/EY) among the HIV-negative and the HIV-positive patients, respectively

32 t and 24 chronic patients who had documented HIV-negative and/or -positive tests.

33 kely to repeat test than individuals testing HIV-negative (aOR 0.17, 95% CI 0.006-0.52).

34 y 6 months provided by participants who were HIV negative at baseline to estimate the primary outcome

35 med consent, and, for this paper, who tested HIV negative at baseline were recruited from the streets

36 infection at PrEP randomization, and 2 were HIV negative at enrollment.

37 All children were HIV negative at testing.

38 ad detectable HIV-1 RNA and 8 of 12 remained HIV negative at their 6-week follow-up visit (4 were los

39 Among the 3,625 enrollees who were HIV-negative at enrollment and completed at least one fo

40 ervational study, HIV patients (n = 457) and HIV-negative blood donors (n = 79) presenting to an HIV

41 of the BTS, non-pregnant, non-breastfeeding, HIV-negative BTS participants, all of whom were current

42 tively), including only infants who remained HIV negative by 36 weeks of age.

43 nes was performed on select HIV-positive and HIV-negative cases in PD-L1+ tumor areas associated with

44 Among 119 HIV-negative cases with confirmed bacterial pneumonia, 7

45 children had increased mortality compared to HIV-negative children (aHR, 6.85; 95% CI, 4.60-10.19) an

46 combining the VTS sample with 629 same-aged HIV-negative children from the local demographic platfor

47 on against coprevalent and incident TB among HIV-negative children younger than 10 years (RR, 0.35; 9

48 with HIV-positive CKD, and 39 patients with HIV-negative CKD), and 108 controls (100%).

49 plasma from 15 human immunodeficiency virus (HIV)-negative classic KS cases to plasma from 29 matched

50 This HIV-negative cohort allowed us to assess cellular immune

51 235 (62%) of 380 sexual partners who tested HIV-negative, compared with eight (18%) of 45 who tested

52 uals put close human immunodeficiency virus (HIV)-negative contacts of HIV-infected persons at increa

53 confers protection against incident TB among HIV-negative contacts younger than 30 years (RR, 0.33; 9

54 ) and compared to those in young and elderly HIV-negative control subjects.

55 ed HIV-positive subjects (ART-Naive), and 22 HIV-negative controls (HIV-Neg).

56 rs and was significantly lower than PS among HIV-negative controls (HR, 1.34; 95% CI, 1.08 to 1.68; P

57 n ART recipients with suppressed viremia and HIV-negative controls (P < .01).

58 s in early ART remained elevated relative to HIV-negative controls (P = .02).

59 ipheral blood mononuclear cells (PBMCs) from HIV-negative controls and HIV-1-infected patients were c

60 s were similar between elite controllers and HIV-negative controls but significantly lower in ART rec

61 d 37 subjects in The Gambia, West Africa: 10 HIV-negative controls, 10 HIV-2-infected subjects with l

62 receiving suppressive cART and 79 comparable HIV-negative controls, aged >/=45 years, from the Comorb

63 Compared with HIV-negative controls, HIV-infected recipients had signi

64 s higher in HIV-positive cases compared with HIV-negative controls.

65 median follow-up, 3.8 years) matched 1:10 to HIV-negative controls.

66 of CD14(++)CD16(+) monocytes, compared with HIV-negative controls.

67 and higher CX3CR1 levels than monocytes from HIV-negative controls.

68 ease of HML-2 RNA in total PBMCs compared to HIV-negative controls.

69 sma HIV type 1 RNA load, <50 copies/mL), and HIV-negative controls.

70 d in both HIV-positive groups, compared with HIV-negative controls.

71 sive and noninvasive serotypes compared with HIV-negative controls.

72 reated HIV-infected patients were matched to HIV-negative controls.

73 -infected patients compared with appropriate HIV-negative controls.

74 ve women naive to antiretroviral therapy and HIV-negative controls.

75 interval [CI], 1.45-2.2; P<0.001) than their HIV-negative counterparts as well as a higher risk of gr

76 ter overall life expectancies than did their HIV-negative counterparts in the general population [29.

77 to having similar chronic diseases as their HIV-negative counterparts, as well as illnesses associat

78 ng with HIV (5.8, 95% CI 4.5-7.4) than their HIV-negative counterparts.

79 aspirates of these individuals compared with HIV-negative counterparts.

80 cted patients are higher than those in their HIV-negative counterparts.

81 HIV-infected individuals compared with their HIV-negative counterparts.

82 etected in 632 human immunodeficiency virus (HIV)-negative couples followed for 2 years in a male cir

83 Genital HPV was assessed in 725 concordant HIV-negative couples and 209 HIV-positive couples enroll

84 pes were detected in both partners in 60% of HIV-negative couples and 96% of HIV-positive couples ove

85 For HIV-negative couples, genotypic concordance was 30% at b

86 V)-positive patients who receive organs from HIV-negative donors has been reported to be similar to t

87 urified pTfh and non-pTfh cells from healthy HIV-negative donors were tested for HIV permissiveness u

88 the levels of IL-2, IL-7, or IL-15, while in HIV-negative donors, memory CD4+ T cell cycling was rela

89 ients as well as in primary myeloid DCs from HIV-negative donors.

90 ce receptor expression in primary cells from HIV-negative donors.

91 ncomitant with altered mDCs and dependent on HIV negative factor (Nef).

92 had significantly lower seroprevalence than HIV-negative females for PV1 (91.8% vs 95.3%; P<.01) and

93 ropositivity for HIV-positive females versus HIV-negative females was 0.95 (95% confidence interval [

94 ) PrEP as part of combination prevention for HIV-negative FSWs and (2) early ART for HIV-positive FSW

95 We enrolled HIV-negative gay and other men who have sex with men who

96 The HIV-positive and HIV-negative groups had comparable median age (21 years)

97 Pa; P < .001); HIV positive/HCV negative and HIV negative/HCV negative women had similar liver stiffn

98 Compared with HIV negative/HCV negative women, HIV positive/HCV positi

99 sociation among HIV positive/HCV negative or HIV negative/HCV negative women.

100 V positive, 14 HIV negative/HCV positive, 57 HIV negative/HCV negative) in the Women's Interagency HI

101 ] negative, 78 HIV positive/HCV positive, 14 HIV negative/HCV positive, 57 HIV negative/HCV negative)

102 fected recipients had worse PS compared with HIV-negative/HCV-infected controls (5-year: 67.0% versus

103 similar for HIV monoinfected recipients and HIV-negative/HCV-negative controls at both times.

104 ource Consortium and 67 seminal samples from HIV-negative healthy controls.

105 However, compared with HIV-negative/hepatitis C virus (HCV)-negative controls,

106 se patients as human immunodeficiency virus (HIV)-negative HHCs with blood samples in whom tuberculos

107 Among 6751 HIV-negative HHCs with baseline blood samples, 192 had s

108 Comparison between these 18 cases and 12 HIV-negative HHV-8-unrelated MCD cases showed marked dis

109 een ARV use and adverse birth outcomes among HIV-negative HIV-exposed infants.

110 encephalitis in both HIV positive (HIV+) and HIV negative (HIV-) subjects is associated with high mor

111 n immunodeficiency virus (HIV) compared with HIV-negative (HIV-) adolescents.

112 the numbers of circulating CD4+ cells in the HIV-negative (HIV-) brain-dead donor (BDD) is not known.

113 areas of dysplasia and 22 patients who were HIV-negative (HIV-) with AGWs seen between February 2013

114 P < .05) and diarrhea (RR, 1.41; P < .05) in HIV-negative household contacts of HIV-infected individu

115 an slum of Kibera (Kenya) that included 1830 HIV-negative household contacts of HIV-infected individu

116 fected individuals compared with exclusively HIV-negative households.

117 and 13 677 individuals living in exclusively HIV-negative households.

118 A total of 2,473 participants who were HIV negative in January 2006 had interviews between then

119 veillance (NHBS) system among MSM who tested HIV negative in NHBS and were currently sexually active.

120 dary influenza-like illness than contacts of HIV-negative index cases.

121 ads) in 11 HIV-positive subjects, but only 1 HIV-negative individual (13.4 versus 1.3%; P = 0.0018).

122 ciency virus (HIV) transmission, in which an HIV-negative individual takes a single daily dose of an

123 s of respiratory and diarrheal infections in HIV-negative individuals >5 years old.

124 HIV-positive individuals than for comparable HIV-negative individuals (8.7 years younger in MACS (P <

125 g was associated with dolichoectasia only in HIV-negative individuals (P = <.001).

126 prevalence in HIV-infected individuals than HIV-negative individuals across all risk groups and regi

127 Cases of NCPH have been reported in HIV-negative individuals as result of treatment with thi

128 Tuberculosis in HIV-negative individuals disproportionately occurs in me

129 equalities in HRQoL between HIV-positive and HIV-negative individuals in this general population samp

130 itiated ART less than 5 years previously and HIV-negative individuals in Zambia (-0.006, 95% CI -0.00

131 However, regular repeat testing by high-risk HIV-negative individuals is important for timely initiat

132 predominantly IgA(+) plasmablast profile in HIV-negative individuals or in aviremic HIV-infected ind

133 Concerns for nephrotoxicity also extend to HIV-negative individuals using tenofovir disoproxil fuma

134 ive individuals and 78 autopsied brains from HIV-negative individuals were stained for metalloprotein

135 In HIV-negative individuals, H. pylori infection was associ

136 itiated ART more than 5 years previously and HIV-negative individuals, neither in Zambia (change in m

137 In HIV-negative individuals, the contribution of the immune

138 in dolichoectasia appears more prominent in HIV-negative individuals, while apoptosis, mediated by c

139 associated with CD68 staining (P = <.001) in HIV-negative individuals, while caspase 3 was associated

140 sitive individuals receiving therapy, and 10 HIV-negative individuals.

141 HIV-positive, ART-naive patients but also in HIV-negative individuals.

142 ers of T-cell activation in HIV-positive and HIV-negative individuals.

143 ationwide HIV cohort and a cohort of matched HIV-negative individuals.

144 requent in BAL of HIV-positive compared with HIV-negative individuals.

145 in prevalence rates between HIV-positive and HIV-negative individuals.

146 HIV-negative injectable progestin-only contraceptive use

147 total number sampled) among HIV-infected and HIV-negative inpatients within 72 hours of hospitalizati

148 We categorised participants as HIV negative, known HIV infected, or newly diagnosed as

149 ransmission from HIV-positive women to their HIV-negative male partners (M-F+) was evaluated.

150 d HSV2-negative women aged 15-49 years whose HIV-negative male partners were concurrently enrolled in

151 Although human immunodeficiency virus (HIV)-negative men having sex with men (MSM) bear a subst

152 d tobacco smoking (1.46 [1.30-1.65]) than in HIV-negative men (both p<0.0001).

153 iagnosed men (from 29% to 67%, p<0.0001) and HIV-negative men (from 26% to 62%, p<0.0001) suggests th

154 rs), and compared them with those in 193 763 HIV-negative men and 222 808 HIV-negative women, respect

155 523 (72%) of 734 HIV-negative men visited a circumcision facility, with n

156 acco use prevalence between HIV-positive and HIV-negative men was not significant (1.26 [1.00-1.58];

157 A total of 4,685 HIV-negative men who have sex with men (MSM) completed b

158 We previously reported on a cohort of HIV-negative men with subclinical endotoxemia linked to

159 etected in 54% of HIV-negative women, 56% of HIV-negative men, and 93% of HIV-positive men and women.

160 HPV infection and anal cancer compared with HIV-negative men.

161 ytokines in semen were highly coregulated in HIV-negative men; however, this network was disrupted du

162 itive mothers shedding at a higher rate than HIV-negative mothers.

163 sex with other partners was reported by 108 HIV-negative MSM (33%) and 21 heterosexuals (4%).

164 er man per year increased from 1.3 to 1.6 in HIV-negative MSM (Ptrend < .0001) and from 1.6 to 2.3 in

165 e conducted a prospective cohort study among HIV-negative MSM aged 18 years or older between 2007 and

166 enital HPV natural history may be similar in HIV-negative MSM and MSW.

167 HIV incidence among a cohort of 276 HIV-negative MSM diagnosed with rectal CT and/or GC in N

168 re at high risk of acquiring HIV (defined as HIV-negative MSM either reporting one or more casual UAI

169 Targeting HIV-negative MSM in a discordant regular partnership is

170 xis is most cost-effective when targeted for HIV-negative MSM in a discordant regular partnership.

171 secondary syphilis for both HIV-positive and HIV-negative MSM nationally, suggesting interruption of

172 HIV-negative MSM with rectal infections (>70% of which w

173 clinics was compared to HIV incidence among HIV-negative MSM without these infections.

174 Compared with HIV-negative MSM, HIV-infected individuals had significa

175 Among HIV-negative MSM, the proportion of infections that were

176 h human immunodeficiency virus (HIV)/AIDS or HIV-negative MSM.

177 50 patients, both HIV-positive (n = 467) and HIV-negative (n = 83), hospitalized with cough >/=2 week

178 12 993 (85%) participants tested HIV negative, of whom 750 (6%) uncircumcised men were ra

179 Participants were identified as HIV negative or positive on the basis of an OraQuick HIV

180 nfection among human immunodeficiency virus (HIV)-negative or HIV-positive couples followed longitudi

181 -long terminal repeat circles (P < .001) and HIV-negative or indeterminate serostatus (P < .001) but

182 potentially discordant partners (PDP; i.e., HIV-negative or unknown-status partners), (c) PDPs with

183 t was >100 cells/mm(3) (>50% neutrophils) in HIV negative participants and >5 cells/mm(3) in HIV posi

184 HIV-positive (94.7% receiving cART) and 520 HIV-negative participants of the AGEhIV Cohort Study, ag

185 T recipients with suppressed viremia, and 35 HIV-negative participants were evaluated.

186 Of the 1200 HIV-negative participants, 1085 (90%) were retained at 1

187 infections by comparing newly diagnosed with HIV-negative participants.

188 IV-1 polymerase and envelope sequences if an HIV-negative partner became infected to determine phylog

189 isk of within-couple HIV transmission to the HIV-negative partner.

190 Although 11 HIV-negative partners became HIV-positive (10 MSM; 1 het

191 In HIV negative patients given MM compared to placebo, mean

192 combination in human immunodeficiency virus (HIV)-negative patients (DA-EPOCH-R group) and a lower-do

193 tumor specimens from 23 HIV-positive and 17 HIV-negative patients (29 men and 11 women; mean [SD] ag

194 dal Lymphoma Study Group-32 (IELSG32) trial, HIV-negative patients (aged 18-70 years) with newly diag

195 HIV-negative patients (aged 18-70 years) with newly diag

196 ve patients and 66% (95% CI, 57% to 74%) for HIV-negative patients (P=not significant).

197 h CA-MRSA at any site: 20% of HIV and 11% of HIV-negative patients (relative prevalence=1.8, P=.002).

198 ed risk factor associations with oral HPV in HIV-negative patients are consistent with sexual transmi

199 of potentially cancerous oral lesions among HIV-negative patients but not among HIV-positive patient

200 s and ocular complications were common among HIV-negative patients even with systemic antibiotic trea

201 HIV-negative patients may be disproportionally responsib

202 ciency virus (HIV)-positive patients and 128 HIV-negative patients presenting for oral examination at

203 in EBC, saliva, urine, or blood samples from HIV-negative patients suspected of having pulmonary tube

204 e likely to be found in HIV-positive than in HIV-negative patients upon hospitalization, and that cau

205 HIV-negative patients with aggressive B-cell lymphoma an

206 The same analyses were performed in HIV-negative patients with cancer (n = 53), hepatitis C

207 We identified seven HIV-negative patients with cryptococcal meningitis who t

208 phenotypic DST heterogeneity, whereas among HIV-negative patients with MDR tuberculosis, the adjuste

209 monoclonal antibody against interleukin 6-in HIV-negative patients with multicentric Castleman's dise

210 When compared to the HIV-positive patients, HIV-negative patients with ocular syphilis were older (P

211 complex adaptive immune response observed in HIV-negative patients with persistent fungal lung infect

212 mples, in a substantial proportion of adult, HIV-negative patients with PTB after a standard 6-month

213 profiles are indistinguishable from those of HIV-negative patients with stable graft function and nor

214 ype for diagnosing pulmonary tuberculosis in HIV-negative patients with the Xpert assay.

215 mission from coinfected patients compared to HIV-negative patients with tuberculosis.

216 ymphovir patients appeared similar to PFS of HIV-negative patients, 86% [82%, 90%], but patients with

217 tic population parameters were compared with HIV-negative patients, and predictive value of the pretr

218 in 32% and 16% of HIV-positive patients and HIV-negative patients, respectively, including high-risk

219 l acuity loss to 20/50 or worse (P = .03) in HIV-negative patients, respectively.

220 Among HIV-negative patients, significant risk factors for oral

221 Among HIV-negative patients, temporary housing (homeless, shel

222 nfection displayed higher risk features than HIV-negative patients.

223 n profiles in anal SCCs from HIV-positive vs HIV-negative patients.

224 s and comparisons with appropriately matched HIV-negative patients.

225 ent (TME) in anal SCCs from HIV-positive and HIV-negative patients.

226 inemia in all HIV-positive patients and some HIV-negative patients.

227 shed data surrounding HHV-8-related CD among HIV-negative patients.

228 ronic illnesses that are often seen in older HIV-negative patients.

229 to MsgC1, MsgC3, MsgC8 and MsgC9 compared to HIV-negative patients.

230 of IFNG in the TME of both HIV-positive and HIV-negative patients.

231 uated for the diagnosis of cryptococcosis in HIV-negative patients.

232 with no significant differences from that of HIV-negative people (change in mean HRQoL score -0.001,

233 aimed to assess these factors in a cohort of HIV-negative people at risk of infection.

234 ed to compare HRQoL between HIV-positive and HIV-negative people in Zambia and South Africa.

235 There was some evidence that HIV-negative people with higher risk sexual behaviours w

236 T (-0.008, -0.01 to -0.004; p=0.001) than in HIV-negative people, but the magnitudes of difference we

237 We enrolled 1603 HIV-negative people, of whom 1225 (76%) received PrEP.

238 roviral therapy (ART) is approaching that of HIV-negative people.

239 y, 3 separate clinical studies of high-risk, HIV-negative persons conducted in Botswana and Thailand.

240 ive population and an emerging concern among HIV-negative persons receiving pre-exposure prophylaxis.

241 The risk of illness among HIV-negative persons was directly proportional to the nu

242 >/=2 years of virologic suppression; at-risk HIV-negative persons were controls.

243 the IgM responses to Msg in HIV-positive and HIV-negative persons with respiratory symptoms.

244 o the costs of ART provision to misdiagnosed HIV-negative persons.

245 lt life expectancy compared with that of the HIV-negative population (ie, the life expectancy deficit

246 In the HIV-negative population, HALE was around 58 years (SD 0.

247 ning and may be useful for further targeting HIV-negative populations for pre-exposure prophylaxis.

248 Compared to HIV-negative populations, HIV patients are particularly

249 HIV-negative pregnant women between 16 and 32 weeks' ges

250 SP) is recommended for malaria prevention in HIV-negative pregnant women, but it is contraindicated i

251 organ is intentionally transplanted into an HIV-negative recipient.

252 t (P>0.05) between HIV-infected patients and HIV-negative recipients (n=22) with stable graft functio

253 levels to achieve an exposure equivalent to HIV-negative recipients is suggested.

254 y 40 % lower compared with AUC's reported in HIV-negative recipients, when similar trough levels were

255 een reported to be similar to the outcome in HIV-negative recipients.

256 rejection (AR) rates are over twice those of HIV-negative recipients.

257 placebo-controlled double-blind study of 162 HIV-negative RV144 vaccine recipients, we evaluated 2 ad

258 cillus, and Atopobium, were detected only in HIV-negative samples.

259 al swabs, urine, and vaginal wash samples of HIV-negative sex workers and HIV-status discordant coupl

260 Testing of plasma samples that were HIV negative showed no false positive results in the det

261 t EBC, saliva, urine, and blood samples from HIV-negative, smear- and culture-positive pulmonary tube

262 We studied these factors in 168 HIV-negative South African adolescent females aged 16 to

263 in skin test-positive (>/=15-mm induration), HIV-negative South African adults.

264 In this prospective cohort, we enrolled HIV-negative South African women aged 18-23 years who we

265 ot consistently restore the microbiota to an HIV-negative state.

266 9 specimens of 21 subjects who followed from HIV negative status.

267 nors, VAX004 vaccine recipients, and healthy HIV-negative subjects using a variety of primary and cel

268 ccus mutans, and Candida, in saliva than did HIV-negative subjects.

269 e (BAL) and mouths of 82 HIV-positive and 77 HIV-negative subjects.

270 All 172 infants tested were HIV-negative (ten untested).

271 Among 601 human immunodeficiency virus (HIV)-negative tested controls, 3% had CRP >/=40 mg/L.

272 an immunodeficiency virus (HIV) positive and HIV-negative tuberculosis disease and of the impact of a

273 nce interval, .24-.96]) than the contacts of HIV-negative tuberculosis patients.

274 HIV-negative uncircumcised men (aged 16-49 years) who co

275 , and viral suppression at 9 months, and for HIV-negative uncircumcised men were visiting a circumcis

276 d HIV-negative women; between 2012 and 2014, HIV-negative VTS children (332 HIV exposed, 574 HIV unex

277 linical screening, 93% of the women who were HIV-negative were confirmed as clinically eligible for P

278 A total of 17,870 persons who were initially HIV-negative were followed for 94,427 person-years; amon

279 t naive or interferon treatment experienced (HIV-negative) were sequentially enrolled at the Clinical

280 portion of all adults (both HIV positive and HIV negative) with a detectable viral load (local preval

281 Human immunodeficiency virus (HIV)-negative women 18-45 years old with 1 or more vagin

282 to those of a historical comparison group of HIV-negative women (n = 267) using univariate methods.

283 In this cohort study, HIV-negative women aged 18-39 years were recruited at tw

284 ce interval [CI], 4.2%-7.8%) for children of HIV-negative women and 10.8% (95% CI, 7.6%-15.2%) for ch

285 Breast milk of HIV-negative women can inhibit HIV infection.

286 It is well documented that breast milk of HIV-negative women can inhibit HIV infection.

287 The CWHS followed 750 HIV-positive and 323 HIV-negative women during 1993-2002.

288 At baseline, HIV+ women compared with HIV-negative women had a higher mean +/- SD food-insecur

289 eficiency virus (HIV)-positive and high-risk HIV-negative women in a longitudinal cohort.

290 The ICER for HIV-negative women was $6.2 per DALY averted.

291 Between 2008-2010, HIV-negative women were enrolled and followed for 12 mon

292 llment, HPV infection was detected in 54% of HIV-negative women, 56% of HIV-negative men, and 93% of

293 hose in 193 763 HIV-negative men and 222 808 HIV-negative women, respectively.

294 infected women with delivery at term or with HIV-negative women.

295 birthweight, and did a separate analysis for HIV-negative women.

296 egnancy for HIV-positive women compared with HIV-negative women.

297 4; P < .001) of oncogenic HPV as compared to HIV-negative women.

298 acco use (1.32 [1.03-1.69]; p=0.030) than in HIV-negative women.

299 tudy (VTS) supported EBF in HIV-positive and HIV-negative women; between 2012 and 2014, HIV-negative

300 undiagnosed HIV-positive youths, and linking HIV-negative youths to relevant prevention services.